Barclays Remains a Hold on Zoetis Inc. (ZTS)

Zoetis Inc. (NYSE:ZTS) is one of the best pet stocks to buy according to hedge funds. Barclays reaffirmed a Hold rating on Zoetis Inc. (NYSE:ZTS) on February 18, setting a price target of $136.00. The rating update came after Zoetis Inc. (NYSE:ZTS) announced fiscal Q4 and full year 2025 results on February 12, reporting revenue of $2.4 billion for fiscal Q4 2025 and reflecting a 3% growth compared to fiscal Q4 2024. Revenue for the quarter rose 4% compared to the prior year period on an organic operational basis, and net income for the quarter reached $603 million, or $1.37 per diluted share, an increase of 4% and 6%, respectively, on a reported basis.

Zoetis Inc. (NYSE:ZTS) further reported $9.5 billion in revenue for the full year 2025, reflecting a growth of 2% compared to full year 2024. On an organic operational basis, revenue for the full year 2025 rose 6%, and net income for the year was $2.7 billion, or $6.02 per diluted share, an increase of 8% and 10%, respectively, on a reported basis.

Zoetis Inc. (NYSE:ZTS) is a global animal health company that focuses on the discovery, development, manufacture, and commercialization of vaccines, medicines, biodevices, genetic tests, diagnostic products, and precision animal health. Its operations are divided into the United States and International segments, with each segment boasting a diversified product portfolio, including vaccines, parasiticides, pain and sedation, animal health diagnostics, and more. The company specializes in products across eight core species: companion animals (dogs, cats, and horses), cattle, swine, livestock (sheep and fish), and poultry.